No association between a candidate TCF7L2 variant and risk of breast or ovarian cancer.

ABSTRACT:

Background

TCF7L2 is a transcription factor involved in Wnt/beta-catenin signaling which has a variant known to be associated with risk of Type 2 diabetes and, in some studies, with risk of certain cancers, including familial breast cancer. No studies of ovarian cancer have been reported to date.

Methods

Two clinic-based case-control studies at the Mayo Clinic were assessed including 798 breast cancer cases, 843 breast cancer controls, 391 ovarian cancer cases, and 458 ovarian cancer controls. Genotyping at TCF7L2 rs12255372 used a 5' endonuclease assay, and statistical analysis used logistic regression among participants as a whole and among a priori-defined subsets.

Results

No associations with risk of breast or ovarian cancer were observed (ordinal model, p = 0.62

SUBMITTER: Goode EL 

PROVIDER: S-EPMC2749057 | biostudies-literature | 2009 Sep

REPOSITORIES: biostudies-literature